Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Interventions for bullous pemphigoid|
|Citation:||The Cochrane Database of Systematic Reviews, 2010; 2010(10):002292-1-002292-62|
|Publisher:||Update Software Ltd|
|Gudula Kirtschig, Philippa Middleton, Cathy Bennett, Dedee F Murrell, Fenella Wojnarowska, Nonhlanhla P Khumalo|
|Abstract:||Background Bullous pemphigoid (BP) is the most common autoimmune blistering disease in the West. Oral steroids are the standard treatment.This is an update of the review published in 2005. Objectives To assess treatments for bullous pemphigoid. Search strategy In August 2010 we updated our searches of the Cochrane Skin Group Specialised Register, the Cochrane Central Register of Controlled Trials (Clinical Trials), MEDLINE, EMBASE, and the Ongoing Trials registers. Selection criteria Randomised controlled trials of treatments for participants with immunofluorescence-confirmed bullous pemphigoid. Data collection and analysis At least two authors evaluated the studies for the inclusion criteria, and extracted data independently. Main results We included 10 randomised controlled trials (with a total of 1049 participants) of moderate to high risk of bias. All studies involved different comparisons, none had a placebo group. In 1 trial plasma exchange plus prednisone gave significantly better disease control at 1 month (0.3 mg/kg: RR 18.78, 95% CI 1.20 to 293.70) than prednisone alone (1.0 mg/kg: RR 1.79, 95% CI 1.11 to 2.90), while another trial showed no difference in disease control at 6 months. No differences in disease control were seen for different doses or formulations of prednisolone (one trial each), for azathioprine plus prednisone compared with prednisone alone (one trial), for prednisolone plus azathioprine compared with prednisolone plus plasma exchange (one trial), for prednisolone plus mycophenolate mofetil or plus azathioprine (one trial), for tetracycline plus nicotinamide compared with prednisolone (one trial). Chinese traditional medicine plus prednisone was not effective in one trial. There were no significant differences in healing in a comparison of a standard regimen of topical steroids (clobetasol) with a milder regimen (RR 1.00, 95% 0.97 to 1.03) in one trial. In another trial, clobetasol showed significantly more disease control than oral prednisolone in people with extensive and moderate disease (RR 1.09, 95% CI 1.02 to 1.17), with significantly reduced mortality and adverse events (RR 1.06, 95% CI 1.00 to 1.12). Authors' conclusions Very potent topical steroids are effective and safe treatments for BP, but their use in extensive disease may be limited by side-effects and practical factors. Milder regimens (using lower doses of steroids) are safe and effective in moderate BP. Starting doses of prednisolone greater than 0.75 mg/kg/day do not give additional benefit, lower doses may be adequate to control disease and reduce the incidence and severity of adverse reactions. The effectiveness of adding plasma exchange, azathioprine or mycophenolate mofetil to corticosteroids, and combination treatment with tetracycline and nicotinamide needs further investigation.|
|Keywords:||Humans; Pemphigoid, Bullous; Niacinamide; Azathioprine; Tetracycline; Prednisone; Prednisolone; Clobetasol; Drugs, Chinese Herbal; Immunosuppressive Agents; Glucocorticoids; Plasma Exchange; Combined Modality Therapy; Drug Therapy, Combination; Randomized Controlled Trials as Topic|
|Rights:||Copyright © 2011 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.|
|Appears in Collections:||Obstetrics and Gynaecology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.